Prolate

Prolate is a preclinical-stage biotechnology company focused on developing conditionally active therapeutics to improve the safety and efficacy of potent biologics. The company's platform utilizes protease-sensitive linkers and masking moieties to ensure that therapeutic activity is localized to the tumor microenvironment, thereby reducing systemic toxicity. Prolate's pipeline primarily targets oncology indications where traditional systemic administration of biologics is limited by off-target effects. By leveraging expertise in protein engineering and cancer biology, Prolate aims to expand the therapeutic window for high-potency modalities such as T-cell engagers and cytokines.